Reuters logo
BRIEF-Neurocrine Biosciences says on July 10, co, Patheon UK Ltd entered into amended, restated product agreement to product agreement entered into on Nov 28
July 12, 2017 / 9:16 PM / 2 months ago

BRIEF-Neurocrine Biosciences says on July 10, co, Patheon UK Ltd entered into amended, restated product agreement to product agreement entered into on Nov 28

July 12 (Reuters) - Neurocrine Biosciences Inc

* Neurocrine Biosciences - On July 10, co, Patheon UK Ltd entered into amended, restated product agreement to product agreement entered into on Nov 28, 2016

* Neurocrine Biosciences - Amended and restated product agreement finalizes batch sizes and corresponding pricing for 80 mg Ingrezza capsules - SEC Filing

* Neurocrine Biosciences - Amended and restated product agreement provides for clarification of testing requirements related to manufacture of Ingrezza Source text: [bit.ly/2ual3H8] Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below